

Switching from Lopinavir-Ritonavir to Raltegravir
SWITCHMRK 1 & 2 Trials

Switching from Lopinavir-Ritonavir to Raltegravir

SWITCHMRK 1 & 2 Trials: Study Design

Study Design: SWITCHMRK 1&2

- **Background:** Randomized, double-blind, double-dummy trial evaluating switch from lopinavir-ritonavir to raltegravir in combination with background therapy.
- **Inclusion Criteria (n = 707 combined)**
 - Age ≥ 18 years
 - HIV RNA < 50 copies/mL for ≥ 3 months
 - On lopinavir-ritonavir
 - CD4 count ≥ 100 cells/mm³
 - No lipid-lowering agent for 12 weeks
- **Treatment Arms***
 - Raltegravir 400 mg BID + background therapy
 - Lopinavir-ritonavir 400-100 mg BID + background therapy


Switch Arm
Raltegravir 400 mg BID
(n = 353)

Continuation Arm
Lopinavir-ritonavir 400-100 mg BID
(n = 354)

*Background therapy in both groups included at least 2 NRTIs

Switching from Lopinavir-Ritonavir to Raltegravir SWITCHMRK 1 & 2 Trials: Results

Week 24: Virologic Response (Non-Completion Counted as Failure)




Virologic Failure: Lopinavir-Ritonavir (N = 4); Raltegravir (N = 12)

Source: Eron JJ, et al. *Lancet*. 2010;375:396-407.

Switching from Lopinavir-Ritonavir to Raltegravir

SWITCHMRK 1 & 2 Trials: Results

Week 24: Virologic Response (Non-Completion Counted as Failure)




Source: Eron JJ, et al. Lancet. 2010;375:396-407.

Switching from Lopinavir-Ritonavir to Raltegravir

SWITCHMRK 1 Trial: Results


SWITCHMRK 1 Week 12: Analysis of Lipids



Switching from Lopinavir-Ritonavir to Raltegravir

SWITCHMRK 2 Trial: Results

SWITCHMRK 2 Week 12: Analysis of Lipids



Switching from Lopinavir-Ritonavir to Raltegravir SWITCHMRK 1 & 2 Trials: Conclusions

Interpretation: “Although switching to raltegravir was associated with greater reductions in serum lipid concentrations than was continuation of lopinavir-ritonavir, efficacy results did not establish non-inferiority of raltegravir to lopinavir-ritonavir.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.

